DOCSLIB.ORG

H1 2021 I Euronext: ALBPS – Nasdaq: BPTS Forward Looking Statements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
H1 2021 I Euronext: ALBPS – Nasdaq: BPTS Forward Looking Statements H1 2021 I Euronext: ALBPS – Nasdaq: BPTS Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and other risks discussed in the Company’s registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the “SEC”), which are available for review at http://www.sec.gov/. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to publicly update or review such statements to reflect events or circumstances after the date of this presentation, except as required by law. 2 Corporate Highlights HQ location: Paris, France Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes Founded: 2006 associated with aging and improving functional outcomes for patients suffering from age-related diseases. Our small molecules are aimed at stimulating biological resilience and are developed through a drug discovery platform based on a reverse Employees: 30 pharmacology approach. Euronext growth (ALBPS) : July 2015 Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment of mobility disability in elderly patients with Nasdaq (BPTS): February 2021 sarcopenia in a Phase 2 clinical study (SARA) in the United States and Europe. It is also being studied for the treatment of severe respiratory manifestations in COVID- 19 in a Phase 2-3 clinical study (COVA) in Europe, Brazil, and the US. A pediatric Market cap: €117M (May 11, 2021) formulation of Sarconeos (BIO101) is being developed with IND granted (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD). Cash: €18.8 M as of December 31, 2020 Key partner: Sorbonne University 3 Executive team Samuel Agus - CMO Stanislas Veillet - Founder & CEO • MD, PhD, Board-certified • PhD in genetics, AgroParisTech Neurologist • 25+ years in biotech; Pharmacia- • 15+ years pharma/biotech Monsanto, Danone Group experience including Abbott, Shire and Teva Pharmaceuticals Pierre Dilda - CSO Waly Dioh - COO • PhD in pharmacology (Paris V) • PhD in phytopathology (Paris XI) • 25 years experience in and MBA pharmaceutical research, in both • 21+ years biotech experience in academic and industrial settings France and the U.S. and R&D at Monsanto Evelyne Nguyen- CFO • 30+ years of experience in Corporate Finance for International Pharma & Biotech companies (BMS, LFB, Nicox SA, ANMPartners) • Expertise in cross-borders transactions between Europe, US and Asia 4 Drug discovery for age-related diseases • Sarconeos (BIO 101) Reverse pharmacology from plant natural molecule for neuromuscular and stimulating biological resilience to drug candidates respiratory diseases • Macuneos (BIO201) for eye diseases Build a Screen in Selection of proprietary cellular models best drug collection of of age related candidates • Small molecules: natural and/or natural molecules diseases and based on NCE (new chemical entity) & analogs from identification animal models • New key target against aging medicinal plant, of targets & of aging or produced under pathways genetic • Preclinical proof-of-concept & safety biotic or abiotic diseases • IP on use, process and composition stress of matter • Second generation drug candidates (BIO103, BIO203) DAPI MHC 5 Our clinical pipeline Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Covid-19 COVA Sarconeos (BIO101) Sarcopenia DMD Dry AMD Macuneos (BIO201) Stargardt 6 2020: A transformational year for Biophytis Clinical Achievements Financial achievements Launch of the new COVA study – COVID-19 • $20.1 million (€16.6 M) raise from • Part 1 first interim analysis achieved (50 patients) with positive Nasdaq IPO in Q1 2021 DMC review in Q1 2021 • Part 2 steadily progressing with 155 patients recruited in May. • €23.4 million raise in private placements The second interim analysis is expected before end Q2 2021 on Euronext in 2020 • Top line results for the full study are expected Q3 2021 • €18.8 million in cash and cash Completion of SARA-INT study recruitment – Sarcopenia equivalents as of December 31, 2020 • Phase 2: Treatment completed for the last patient in December 2020 • Top-line results expected in Q2 2021 IND Approval to start MYODA - DMD • US IND & Belgium authorization obtained • Study to start by H1 2021 depending on the evolution of the pandemic 7 Sarconeos (BIO101) activates MAS receptor, triggering key pathways for muscle metabolism, with the potential to stimulate mobility and respiratory functions Sarconeos (BIO101) triggers two important MAS receptor downstream signaling-pathways Sarconeos in myocytes: (BIO101) • PI3K/AKT/mTOR: Increases MAS protein synthesis Receptor • AMPK/ACC: Stimulates energy production MAS activation in skeletal and smooth muscles stimulates muscle metabolism and strength with a potential impact on mobility or respiratory functions Protein Energy Synthesis Production AKT AMPK Pathway Pathway 8 Sarconeos (BIO101) activates the protective arm of the Renin Angiotensin System (RAS) with the potential to stimulate respiratory function in COVID-19 patients • Sarconeos (BIO101) activates the MAS receptor, a key component of Renin SARS-CoV2 the protective arm of the Renin- (Covid-19) Angiotensin System (RAS), known for protecting muscles against catabolism, inflammation or Ace fibrosis Ace2 • The production of Ang 1-7, the Sarconeos (BIO101) natural ligand of MAS receptor, is impaired by SARS-CoV-2, which RAS RAS uses ACE2 to penetrate the lungs, classical protective causing respiratory failures arm arm Muscle • Sarconeos (BIO101) by reactivating catabolism the RAS protective arm, has the Inflammation potential to restimulate respiratory fibrosis capacity in COVID-19 patients. senescence 9 Sarconeos (BIO101) improves muscle strength and mobility in animal models Preservation of muscle strength Beneficial effect on mobility in immobilized mice in aged mice fed with high fat diet1 Administration of 50 mg/kg/day of Administration of 50 mg/kg/day of Sarconeos (BIO101) demonstrated a preservation of Sarconeos (BIO101) demonstrated a statistically muscle strength while immobilized (d0-d14) significant (p<0.01) improvement in maximum compared to vehicle control in hind limb- running velocity (Vmax) compared to “old” control immobilized mice mice, compensating almost completely for the loss of mobility due to aging 1. Results were presented in a poster at the SCWD conference in December 2016 in Berlin, Germany. 10 Sarconeos (BIO101) improves respiratory functions in animal models Improves lungs Improves respiratory function mechanical (Plethysmography) properties (Flexivent) Chronic (8 week) daily administration of C57BL10-mdx mice treated with 50 50 mg/kg/day of Sarconeos (BIO101) mg/kg/day of Sarconeos (BIO101) over 8 statistically significantly (p<0.001) weeks showed an improvement in airway improved lungs mechanical properties responsiveness (PenH) as compared to measured by airway resistance untreated control C57BL10-mdx mice Results were presented in October 2019 during the WMS conference in Copenhagen with posters, and in March 2019 at the annual international congress of Myology in Bordeaux, France 11 Sarconeos (BIO101) results in Phase 1 study (SARA-PK) ELDERLY HEALTHY VOLUNTEERS Sarconeos (BIO101) showed a dose dependent effect on biomarkers of muscle growth and repair (PIIINP) and a dose dependent negative effect on muscle wasting (myoglobin) Single and multiple ascending doses tested in 54 healthy adult and elderly (over 65 years) volunteers Safety profile: No Severe Adverse Events Two active doses (175 & 350 mg b.i.d.) have been selected for the upcoming Phase 2 studies 12 COVA Study: targeting hospitalized patients with respiratory failure, and not intubated Targeted populations Severe cases: signs of respiratory Critical cases: de-compensation, not Patients aged 45 and above, with proven COVID-19, requiring requiring ventilation and severe respiratory symptoms: mechanical • With evidence of respiratory decompensation ventilation ≤7 days before start of study medication, meeting one 5% 45+ of the following: 14% • Tachypnea: ≥ 25 breaths per minute • Arterial oxygen saturation ≤92% 81% Allowed medications: Adapted from Wu et al. • Antiviral agents such as Remdesivir, Bamlanivimab, JAMA, 2020 • Anti- inflammatory agents such as Dexamethasone Mild cases: infection without or with mild signs of pneumonia
Load more

Recommended publications
  • Liste Des Actions Concernées Par L'interdiction De Positions Courtes Nettes
    Liste des actions concernées par l'interdiction de positions courtes nettes L’interdiction s’applique aux actions listées sur une plate-forme française et relevant de la compétence de l’AMF au titre du règlement 236/2012 (information disponible dans les registres ESMA). Cette liste est fournie à titre informatif. L'AMF n'est pas en mesure de garantir que le contenu disponible est complet, exact ou à jour. Compte tenu des diverses sources de données sous- jacentes, des modifications pourraient être apportées régulièrement. Isin Nom FR0010285965 1000MERCIS FR0013341781 2CRSI FR0010050773 A TOUTE VITESSE FR0000076887 A.S.T. GROUPE FR0010557264 AB SCIENCE FR0004040608 ABC ARBITRAGE FR0013185857 ABEO FR0012616852 ABIONYX PHARMA FR0012333284 ABIVAX FR0000064602 ACANTHE DEV. FR0000120404 ACCOR FR0010493510 ACHETER-LOUER.FR FR0000076861 ACTEOS FR0000076655 ACTIA GROUP FR0011038348 ACTIPLAY (GROUPE) FR0010979377 ACTIVIUM GROUP FR0000053076 ADA BE0974269012 ADC SIIC FR0013284627 ADEUNIS FR0000062978 ADL PARTNER FR0011184241 ADOCIA FR0013247244 ADOMOS FR0010340141 ADP FR0010457531 ADTHINK FR0012821890 ADUX FR0004152874 ADVENIS FR0013296746 ADVICENNE FR0000053043 ADVINI US00774B2088 AERKOMM INC FR0011908045 AG3I ES0105422002 AGARTHA REAL EST FR0013452281 AGRIPOWER FR0010641449 AGROGENERATION CH0008853209 AGTA RECORD FR0000031122 AIR FRANCE -KLM FR0000120073 AIR LIQUIDE FR0013285103 AIR MARINE NL0000235190 AIRBUS FR0004180537 AKKA TECHNOLOGIES FR0000053027 AKWEL FR0000060402 ALBIOMA FR0013258662 ALD FR0000054652 ALES GROUPE FR0000053324 ALPES (COMPAGNIE)
    [Show full text]
  • Korian Universal Registration Document 2020 EN V7
    UNIVERSAL REGISTRATION DOCUMENT Annual Financial Report and Integrated Report 2020 Contents Korian, the leading European Activities and performance analysis 249 care services group for elderly 5.1 2020 highlights 250 1 and fragile people 5 5 5.2 Activity overview 252 Presentation of the Korian Group 7 5.3 Review of consolidated results Korian faces Covid-19 pandemic 29 and financial position Our ecosystem and ESG challenges 33 at 31 December 2020 254 Our strategy 41 5.4 Proposed allocation of profit and dividend payment 261 Governance, internal control and risk management 51 5.5 Legal and arbitration proceedings 262 Our business model 57 5.6 Significant changes in the Group’s financial position since the end of the last financial year 262 Risk factors 61 5.7 Material events since the year-end 262 2.1 Operational risks 63 5.8 Foreseeable changes – outlook 264 2 2.2 Strategic risks 68 2.3 Legal, ethical and regulatory risks 69 Financial statements for the year 2.4 Economic and financial risks 71 ended 31 December 2020 265 2.5 Internal control and risk 6.1 Consolidated financial statements management 74 6 for the year ended 31 December 2020 266 Environmental, social and 6.2 Statutory Auditors’ report on the consolidated financial corporate governance 81 statements 321 3.1 Deploying an ESG strategy that 3 6.3 Annual financial statements advances the Group's social mission 84 at 31 December 2020 325 3.2 Providing care excellence whilst ensuring dignity and choice 101 6.4 Statutory Auditors’ report on the annual financial statements 343 3.3
    [Show full text]
  • Sycomore Partners
    RESPONSIBLE RE INVESTOR REPORT PORT SYCOWAY AS AN INVESTOR SYCOMORE PARTNERS Report published on June 30th 2020 pertaining to the Sycomore Partners fund and compliant with the requirements of Article 173-VI of law n°2015-992 of August 17th 2015 on the “energy transition for green growth” as of December 31st 2019. This report concerns the Sycomore Partners fund, a strategy managed on the basis INTR of systematic “sustainable development” integration. It should be read together with Sycomore AM’s “Sycoway as an Investor” report. This publication describes how the analysis we conducted on companies impacted the management of the fund and the ODU sustainable development performance of our investments as of December 31st 2019. It is compliant with Article 173-VI of law n°2015-992 of August 17th 2015 on the “energy CTI transition for green growth”. For more information on the methods and resources used in the sustainable development-driven analysis of the investment universe, please consult ION Sycomore AM’s “Sycoway as an Investor” report. Sustainable development performance of 01 SYCOMORE PARTNERS The SPICE RATINGS Sycomore Partners is a fund that systematically takes into account sustainable development considerations, based on our fundamental corporate analysis model, SPICE(1). Note, however, that stocks are not selected for the portfolio on the basis of sustainable development criteria, meaning that the fund’s investment universe is not determined through additional sustainability screenings. We assess the sustainable development performance
    [Show full text]
  • REGISTRATION DOCUMENT Annual Financial Report and Integrated Report
    2018 REGISTRATION DOCUMENT Annual Financial Report and Integrated Report In caring hands 2018 REGISTRATION DOCUMENT Annual Financial Report and Integrated Report This registration document was filed with the Autorité des marchés financiers (French Financial Markets Authority – “AMF”) on 25 April 2019, in accordance with article 212-13 of its General Regulation. It may be used in support of a financial transaction if accompanied by a prospectus approved by the AMF. This document has been prepared by the issuer and is binding for its signatories. The registration document may be viewed free of charge upon request to the Company and on the Company’s website (www.korian.com) and on the AMF’s website (www.amf-france.org). Historical financial information Pursuant to article 28 of European Commission Regulation (EC) No. 809/2004, the following information is included by reference in this registration document: • the key figures given on page 7, and the consolidated financial statements for the financial year ended 31 December 2017, the notes to the financial statements, the Statutory Auditors’ report as presented on pages 143 to 210 of the 2017 registration document filed with the AMF on 26 April 2018 under No. D.18-0411. • the consolidated financial statements for the financial year ended 31 December 2016, the notes to the financial statements, the Statutory Auditors’ report as presented on pages 143 to 204 of the 2016 registration document filed with the AMF on 26 April 2017 under No. D.17-0432. KORIAN • 2018 REGISTRATION DOCUMENT 1 Contents
    [Show full text]
  • Bonne Résilience Des Activités De Korian En 2020 Dans Le Contexte De La Pandémie De Covid-19
    COMMUNIQUE DE PRESSE Bonne résilience des activités de Korian en 2020 dans le contexte de la pandémie de Covid-19 Poursuite de l’expansion géographique maîtrisée avec l’acquisition d’un réseau de 6 résidences seniors premium au Royaume-Uni Paris, 24 février 2021 - Korian, premier Groupe européen de Soin au service des personnes âgées et fragiles, annonce son chiffre d’affaires du quatrième trimestre et ses résultats pour l’exercice 2020. Sophie Boissard, administratrice et directrice générale du groupe Korian : "À l’heure où nous dressons le bilan de l’année passée, nos premières pensées vont aux résidents, patients et collaborateurs du Groupe qui ont été touchés par la pandémie, ainsi qu’à leurs proches. Je salue l’engagement et la solidarité dont ont fait preuve les équipes Korian pour assurer la continuité et la qualité des soins face à une menace sanitaire d’une ampleur inédite. Cette épreuve nous a ramenés à l’essence même de notre mission : prendre soin des personnes âgées et fragiles et de leurs proches, dans le respect de leur dignité, et contribuer à leur qualité de vie. Elle nous a confortés dans la force de nos valeurs : Confiance, Initiative, Responsabilité. En 2021, face au défi de la longévité et des maladies chroniques, nous continuerons plus que jamais à investir et à innover pour apporter à chaque personne des solutions de qualité adaptées à sa situation. » Forte mobilisation à l’échelle européenne pour faire face à la pandémie : - Déploiement dans tous les établissements Korian de protocoles Covid adaptés, audités par Bureau Veritas, sécurisation des approvisionnements, 100 000 tests effectués par semaine ; 76% des résidents1 et 43% des collaborateurs2 vaccinés.
    [Show full text]
  • Korian Enters Into Exclusive Negotiations to Sell Two Portfolios of Long Term Care Facilities in France to Accelerate Its Multilocal Care Approach
    PRESS RELEASE Korian enters into exclusive negotiations to sell two portfolios of long term care facilities in France to accelerate its multilocal care approach . Ambitious transformation plan ongoing in France covering 46% of the nursing home network by 2024 . Relocation, renovation or extension of 24 facilities . “Boost” refurbishment programme of 90 facilities . Korian enters into exclusive negotiations with : o Colisée for the sale of 21 facilities and o Vivalto Vie for 11 facilities . The 32 facilities represent € c. 85 million in 2020 . The negotiation includes the buildings of 11 sites . An operation to streamline the service offering in France and to concentrate on living areas where the Group has long term care, healthcare and community care capacity . Demanding selection process of the buyers to ensure continued high quality of care and social commitments going forward Paris, 2nd July, 2021 - Korian, the leading European care services group for elderly and fragile people, pursues the transformation and repositioning of its nursing home portfolio in France. In parallel with the continued investment into the network through the renovation, extension or relocalisation of facilities (24 projects underway) and the modernisation of around 90 sites by end 2021, Korian is preparing to sell 32 facilities in two separate portfolios. Korian owns the buildings for 11 of them and the real estate is sold with the operations. Korian has entered exclusive negotiations with Colisée to sell 21 facilities representing € c.48 million of revenue in 2020 and Vivalto Vie to sell 11 facilities representing € 36 million in 2020. The sites concerned by these negotiations are across ten regions in France.
    [Show full text]
  • 30.07.21 Creation of Korian France Site Web 0.Pdf
    PRESS RELEASE Paris, 30 July 2021 Creation of Korian France Korian announces the creation of Korian France, its subsidiary dedicated to managing the Group's operational activities in France. Korian France is the result of a partial asset contribution (apport partiel d’actif) from Korian to Korian France of its "France support functions" (the “Contribution”), a business transfer (cession de fonds de commerce) from Medica France to Korian France and several contributions in kind of shares from Korian to Korian France. The Contribution and the business transfer will be effective on 1st August 2021, at zero hour, and the contributions in kind on 15 August 2021 at the latest. Pursuant to Articles L. 236-18 and L. 228-65, I, 3° of the French Commercial Code and the terms and conditions of the subscription agreements, Korian’s bondholders who have to deliberate on the contemplated Contribution have been consulted. The contemplated Contribution has been approved by all abovementioned bondholders except the holders of €400,000,007.82 bonds convertible into new shares and/or exchangeable for existing shares due 6 March 2027 issued on 6 March 2020 (the “OCEANE”) and the holders of €300,000,014.51 2.50 per cent undated unsubordinated unsecured bonds convertible into new shares and/or exchangeable for existing shares due 31 December 2022 issued on 3 July 2017 and 21 September 2018 (the “ODIRNANE”). Therefore, and given the circumstances, Korian’s Board of Directors held on 29 July 2021 decided to override the non-approval of the contemplated Contribution by the aforementioned bondholders and to carry out the Contribution (the “Decision”) pursuant to the provisions of Article L.
    [Show full text]
  • Report #2 2019
    REPORT #2 2019 In caring hands On the front cover: “I had the honor of being chosen to create a work of art for the 15th anniversary of Korian. When I have met the teams last September, I discovered the Group through them, by spending time with them and the elders in the Korian homes, and by taking knowledge of the books “Tous Positive Care” and “Vivre”. I appreciated the tone and the perception of the elderly This is a subject that touches me and it is for me a major issue of our modern society: to take a close and careful look on aging and its difficulties. It has inspired me so much, that it has become not a work of art but three immersive spaces and a participatory work that have been created and realized to celebrate 15 years of experience and human adventures around Positive Care.” Véronique Le Mouël, visuel artist http://veroniquelemouel.com/?actions=oeuvres-nouvelles 2 KORIAN • REPORT #2 2019 REPORT #2 2019 Contents P5 INTRODUCTION BY SOPHIE BOISSARD P7 ABOUT US P19 THE ISSUES WE FACE P27 OUR STRATEGY P53 OUR GOALS FOR THE FUTURE www.korian.com KORIAN • REPORT #2 2019 3 Our mission is to be a trusted partner for elderly and vulnerable people and their families by providing personalised care and a better quality of life each day. 4 KORIAN • RAPPORT #2 2019 KORIAN: DRIVEN BY DEDICATION Sophie Boissard or the second year in a row, we are publishing an “integrated” report, Korian group Chief which provides a broader perspective of our strategy, our social Executive Office mission and the issues we face, and outlines our model for balanced Chairperson of growth and shared value creation.
    [Show full text]
  • Aedifica and Korian Invest in the Construction of Care Residence in the Netherlands
    PRESS RELEASE 26 January 2021 – after closing of markets Under embargo until 17:40 CET AEDIFICA Public limited liability company Public regulated real estate company under Belgian law Office: Rue Belliard 40 (box 11), 1040 Brussels Enterprise number: 0877.248.501 (RLE Brussels) (the ‘Company’) Aedifica and Korian invest in the construction of care residence in the Netherlands - Acquisition of a care residence to be constructed in Blaricum (Netherlands) by the joint venture between Aedifica and Korian - Total investment: approx. €8 million (50% financed by Aedifica) - Capacity: 29 residents - Initial gross rental yield: approx. 5.5 % - Operator: Korian group under the Stepping Stones label - Expected completion date: Q2 2022 Stefaan Gielens, CEO of Aedifica, commented: “Aedifica and Korian are expanding their joint venture's portfolio in the Netherlands and will invest approx. €8 million in the construction of a brand- new care residence in Blaricum. We are very pleased to further expand our cooperation with the Korian group, which we announced in December.Thanks to our combined experience, even more elderly people in the Netherlands will be able to benefit from sustainable and innovative care concepts that put residents centre stage and give them the space to receive care in the way they prefer.” Eric Scheijgrond, Country Manager of Aedifica Netherlands, adding: “This care residence will provide a new home for 29 elderly people requiring continuous care. In the design, special attention was paid to environmental standards and the energy efficiency of the building. In addition, we used natural building elements as much as possible. The project is expected to be completed in the second quarter of 2022.” 1/6 PRESS RELEASE 26 January 2021 – after closing of markets Under embargo until 17:40 CET Aedifica and Korian are investing approx.
    [Show full text]
  • Investment Committee Paper Korian
    PRIVATE EQUITY CHALLENGE INVESTMENT COMMITTEE PAPER KORIAN Lorenzo Redaelli 27205 | Maria Moreira 22188 | Miguel Meco 21983 | Tiago Marques 22062 January 2018 1. Executive Summary 2. Company Overview 3. Industry Overview 4. Investment Thesis 5. Value Creation Strategy 6. Business Plan 7. Valuation and Capital Structure 8. LBO Model and Exiting 9. Due Diligence 10. Conclusion 11. Appendix 2 Executive Summary Industry & Business Overview Korian SA is the European Leader of Elderly Care. It operates at all the levels of dependency, from home care, assisted living, nursing homes and specialized clinics. It is currently present in 4 countries: France, Germany, Italy and Belgium. The Elderly Care market shows very robust growth trends. It is estimated that the population over 80 in Europe will increase by a CAGR of 2.4% over the next 15 years. Furthermore, the prevalence of elderly-related diseases (such as Alzheimer’s) will further drive the demand for nursing homes and professionalized nursing care. This market is highly fragmented, with considerable economies of scale. This means that M&A can further drive growth, through the acquisition of smaller operators. Finally, Korian operates in a non-cyclical industry, which ensures stability of cash flows and good performance of the buyout regardless of economic conditions. Investment Thesis 1 Consolidation of smaller operators, in a highly fragmented market 2 Internationalization to Sweden, a shifting market with opportunities for private operators 3 Operational Turnaround in Germany, addressing the staffing problem through Korian’s international network 4 Real Estate Portfolio optimization, and capital shift to care provision, Korian’s core business Value Creation Topline growth of 10% CAGR, with a network expansion in the countries where Korian operates of 23,000 beds in 310 facilities.
    [Show full text]
  • Euro Stoxx® Total Market Small Index
    EURO STOXX® TOTAL MARKET SMALL INDEX Components1 Company Supersector Country Weight (%) BE SEMICONDUCTOR Technology Netherlands 1.34 DIALOG SEMICON Technology Germany 1.32 Valmet Industrial Goods & Services Finland 1.19 EVOTEC Health Care Germany 1.18 BANK OF IRELAND GROUP Banks Ireland 1.11 SOITEC Technology France 1.09 BANCO BPM Banks Italy 1.07 TAG IMMOBILIEN AG Real Estate Germany 1.07 WIENERBERGER Construction & Materials Austria 1.03 INTERPUMP GRP Industrial Goods & Services Italy 1.03 COFINIMMO Real Estate Belgium 0.97 AEDIFICA Real Estate Belgium 0.92 SHOP APOTHEKE EUROPE Personal Care, Drug & Grocery Stores Germany 0.85 ALTEN Technology France 0.83 SPIE Construction & Materials France 0.77 BCO SABADELL Banks Spain 0.77 ITALGAS Utilities Italy 0.76 FREENET Telecommunications Germany 0.75 MORPHOSYS Health Care Germany 0.74 ALSTRIA OFFICE REIT Real Estate Germany 0.74 SOLVAC Chemicals Belgium 0.71 ARCADIS Construction & Materials Netherlands 0.70 GERRESHEIMER Health Care Germany 0.69 KONECRANES Industrial Goods & Services Finland 0.69 TIETOEVRY Technology Finland 0.68 GRAND CITY PROPERTIES Real Estate Germany 0.67 SOPRA STERIA GROUP Technology France 0.65 VARTA AG Industrial Goods & Services Germany 0.64 DE LONGHI Consumer Products & Services Italy 0.64 CORBION Food, Beverage & Tobacco Netherlands 0.64 VIDRALA Industrial Goods & Services Spain 0.64 CA IMMOBILIEN ANLAGEN Real Estate Austria 0.63 BUZZI UNICEM Construction & Materials Italy 0.63 VISCOFAN Food, Beverage & Tobacco Spain 0.62 AZIMUT HLDG Financial Services Italy 0.62
    [Show full text]
  • Press Release AFEP LARGE MEMBER COMPANIES INVEST in CLIMATE
    Press release Paris – July 7, 2021 AFEP LARGE MEMBER COMPANIES INVEST IN CLIMATE ACTION WITH CONCRETE PROJECTS Ahead of the COP 26, AFEP launches Ambition 4 Climate, a platform to present on- going low-carbon projects and dialogue with stakeholders While green transition is a major concern and a driver for action, the members of the French Association of Large Companies (AFEP) are committed to tackle the climate emergency. As part of their climate strategy, they are developing a diversity of replicable low-carbon projects that provide concrete solutions to contribute to the climate neutrality challenge. AFEP launches the platform Ambition 4 Climate, which illustrates large companies’ mobilisation to reduce their greenhouse gas (GHG) emissions throughout their value chains with specific examples in a wide range of economic sectors. Being ambitious for the climate means acting! Ambition 4 Climate is a dedicated Internet platform that brings together concrete initiatives taken by AFEP member companies to fight climate change. While investing in various know-how, innovations and technologies, large French companies are implementing operational low-carbon solutions throughout their value chains. Beyond their own action, they are triggering a leverage effect on their ecosystems. Ambition 4 Climate brings together a variety of actions currently being implemented by companies from different sectors to reduce their GHG emissions and those of their suppliers, customers, and partners. These projects, presented in the form of factual data and figures, result from recent investment decisions. They lead to significant changes in production processes, products, and everyday business life. For each project, the carbon impact is assessed according to a detailed methodology.
    [Show full text]